Gao Fei, Wang Yongcun, Li Hao, Yin Jilai
Laboratory, The First Affiliated Hospital of Hainan Medical College, Haikou, Hainan, China.
District One of Cancer Center, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China.
Technol Health Care. 2024;32(5):3083-3095. doi: 10.3233/THC-231681.
Cervical cancer (CC) is a common female malignancy, with a global incidence rate second only to breast cancer.
To propose a new idea for early treatment and auxiliary diagnosis of CC by exploring the diagnostic and prognostic implications of serum miR-182 in CC.
We enrolled 70 CC patients, 35 cervical intraepithelial neoplasia (CIN) patients and 35 healthy controls (HCs), who visited The First Affiliated Hospital of Hainan Medical College Hospital between January 2015 and April 2016. miR-182 expression was quantified by real-time quantitative PCR and compared among the three groups. The correlation of serum miR-182 expression with patients' clinical features was evaluated. The receiver operating characteristic curve (ROC) and the Kaplan-Meier method were used to evaluate the early diagnostic value and prognostic value of serum miR-182. Cox regression analysis was performed to determine serum miR-182 expression and its important role in predicting CC patients' prognosis.
Serum miR-182 expression was determined to be 0.345 ± 0.094, 0.369 ± 0.076, and 0.586 ± 0.157 in CC patients, CIN patients, and HCs, respectively (P< 0.001). Serum miR-182 expression had an obvious association with lymph node metastasis and pathological differentiation (P< 0.05). The area under the ROC curve (AUC) of serum miR-182 was 0.709 (95% CI: 0.622-0.795), the critical value was 0.456, the sensitivity was 81.4%, and the specificity was 52.9%. CC patients were grouped as either the low- (miR-182 < 0.3) or high-level group (miR-182 ⩾ 0.03) based on serum miR-182 levels, and a Cox regression model of OS was established. Serum miR-182 expression was identified as a factor independently influencing CC patients' OS (P= 0.028); the death risk of the high-level group was 3.246 times that of the low-level group.
Serum miR-182 expression is not only a biomarker for early diagnosis of CC, but also one of the independent factors influencing the survival and prognosis of CC patients.
宫颈癌（CC）是一种常见的女性恶性肿瘤，全球发病率仅次于乳腺癌。
通过探索血清miR - 182在宫颈癌中的诊断及预后意义，为宫颈癌的早期治疗及辅助诊断提出新思路。
选取2015年1月至2016年4月期间就诊于海南医学院第一附属医院的70例宫颈癌患者、35例宫颈上皮内瘤变（CIN）患者和35例健康对照者（HCs）。采用实时定量PCR法对miR - 182表达进行定量，并比较三组间差异。评估血清miR - 182表达与患者临床特征的相关性。采用受试者工作特征曲线（ROC）及Kaplan - Meier法评估血清miR - 182的早期诊断价值及预后价值。进行Cox回归分析以确定血清miR - 182表达及其在预测宫颈癌患者预后中的重要作用。
宫颈癌患者、CIN患者及健康对照者血清miR - 182表达水平分别为0.345±0.094、0.369±0.076和0.586±0.157（P<0.001）。血清miR - 182表达与淋巴结转移及病理分化明显相关（P<0.05）。血清miR - 182的ROC曲线下面积（AUC）为0.709（95%CI：0.622 - 0.795），临界值为0.456，灵敏度为81.4%，特异度为52.9%。根据血清miR - 182水平将宫颈癌患者分为低水平组（miR - 182<0.3）和高水平组（miR - 182⩾0.3），并建立总生存期（OS）的Cox回归模型。血清miR - 182表达被确定为独立影响宫颈癌患者OS的因素（P = 0.028）；高水平组的死亡风险是低水平组的3.246倍。
血清miR - 182表达不仅是宫颈癌早期诊断的生物标志物，也是影响宫颈癌患者生存及预后的独立因素之一。
